(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of 817.16% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.73%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.58%.
Abeona Therapeutics's revenue in 2026 is $400,000.On average, 9 Wall Street analysts forecast ABEO's revenue for 2026 to be $6,195,698,303, with the lowest ABEO revenue forecast at $4,239,877,893, and the highest ABEO revenue forecast at $7,983,471,303. On average, 8 Wall Street analysts forecast ABEO's revenue for 2027 to be $11,278,847,965, with the lowest ABEO revenue forecast at $9,410,871,751, and the highest ABEO revenue forecast at $14,268,043,438.
In 2028, ABEO is forecast to generate $16,841,591,172 in revenue, with the lowest revenue forecast at $13,919,592,986 and the highest revenue forecast at $21,036,544,427.